After Hours
There may be slightly higher risks associated with pre-market and after-hours trading than during regular market hours. Due to the fact that issuers often announce critical financial information outside of regular trading hours, extended-hours trading may result in wider spreads for particular securities. Earlier, Yahoo Finance discussed this stock as it revealed Avenue Therapeutics to Present BAER-101 Preclinical Data at American Society for Experimental Neurotherapeutics (ASENT) 2024 Annual Meeting.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Stocks Info
As a NASDAQ listed company, ATXI falls under the Healthcare sector while operating within the Biotechnology industry segment. At the end of the last regular session, the stock closed at $0.17 and fluctuated between $0.1850 as its day high and $0.1620 as its day low. The current market capitalization of Avenue Therapeutics Inc is $6.53M. A total of 2.91 million shares were traded on the day, compared to an average of 5.37M shares.
In the most recent transaction, Davidow Robert L sold 353,000 shares of ATXI for 0.14 per share on Dec 11 ’23. After the transaction, the 10% Owner now owns 22,000 company shares. In a previous transaction on Dec 11 ’23, Davidow Robert L sold 264,000 shares at 0.14 per share. ATXI shares that 10% Owner owns now total 681,000.
Among the insiders who bought shares, Fortress Biotech, Inc. acquired of 418,410 shares on Sep 08 ’23 at a per-share price of $0.72. This resulted in the 10% Owner holding 1,032,390 shares of ATXI after the transaction. In another insider transaction, ROSENWALD LINDSAY A MD bought 348,675 shares at $0.72 per share on Sep 08 ’23. Company shares held by the Director now total 354,318.
In spite of price targets being rarely accurate, it tends to exert some kind influence from time to time, and was often accepted by the market as having some value. In terms of 52-week highs and lows, ATXI has a high of $1.36 and a low of $0.11.
As of this writing, ATXI has an earnings estimate of -$0.1 per share for the current quarter. EPS was calculated based on a consensus of 2 estimates, with a high estimate of -$0.09 per share and a lower estimate of -$0.11. The company reported an EPS of -$0.52 in the last quarter, which was -79.30% lower than expectations of -$0.29.
Balance Sheet Annually/Quarterly
The balance sheet of a company shows what assets and liabilities a company has, as well as the amount, equity investors have invested. With the help of this information, a company’s financial ratios can be calculated to give investors an overview of the company’s prospects. ATXI’s latest balance sheet shows that the firm has $3.76M in Cash & Short Term Investments as of fiscal 2021. Its Book Value Per Share was -$0.41, while its Total Shareholder’s Equity was $3.45M.
Analysts Opinion
The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for ATXI is Buy with a score of 5.00.
